ES2142825T3 - Uso de 1(rs)-(1-trifluoroacetil-2-metilpropil)amida de 4-(4-clorofenil-sulfonilcarbamoil)benzoil-l-valil-l-prolina para la preparacion de un medicamento para el tratamiento de enfermedades vasculares. - Google Patents

Uso de 1(rs)-(1-trifluoroacetil-2-metilpropil)amida de 4-(4-clorofenil-sulfonilcarbamoil)benzoil-l-valil-l-prolina para la preparacion de un medicamento para el tratamiento de enfermedades vasculares.

Info

Publication number
ES2142825T3
ES2142825T3 ES92911644T ES92911644T ES2142825T3 ES 2142825 T3 ES2142825 T3 ES 2142825T3 ES 92911644 T ES92911644 T ES 92911644T ES 92911644 T ES92911644 T ES 92911644T ES 2142825 T3 ES2142825 T3 ES 2142825T3
Authority
ES
Spain
Prior art keywords
chlorophenyl
proline
amide
treatment
vascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92911644T
Other languages
English (en)
Inventor
Jawehar Lal Uf College O Mehta
Tom Gustave Per Saldeen
Wilmer Wayne Nichols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ES2142825T3 publication Critical patent/ES2142825T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radar Systems Or Details Thereof (AREA)

Abstract

SE PRESENTA EL USO DEL 1(RS)-(1-TRIFLUOROACETIL-2-METILPROPIL)AMIDO DE 4-(4-CLOROFENIL-SULFONILCARBAMOIL)BENZOIL-L-VALIL-L-PROLINA INHIBIDOR DE LA ELASTASA, O DE UNA SAL FARMACEUTICAMENTE ACEPTABLES DEL MISMO, EN EL TRATAMIENTO DE CIERTAS ENFERMEDADES VASCULARES EN LAS QUE ESTAN INVOLUCRADOS NEUTROFILOS, POR EJEMPLO LAS ENFERMEDADES CARDIOVASCULARES TALES COMO LA ISQUEMIA DE MIOCARDIO, ENFERMEDADES CEREBROVASCULARES TALES COMO LOS DERRAMES, ENFERMEDADES VASCULARES PERIFERICAS TALES COMO LA COJERA INTERMITENTE, ASI COMO LOS ESTADOS DE REPERCUSION TALES COMO LOS ASOCIADOS CON LA CIRUGIA VASCULAR RECONSTRUCTIVA.
ES92911644T 1991-06-18 1992-06-17 Uso de 1(rs)-(1-trifluoroacetil-2-metilpropil)amida de 4-(4-clorofenil-sulfonilcarbamoil)benzoil-l-valil-l-prolina para la preparacion de un medicamento para el tratamiento de enfermedades vasculares. Expired - Lifetime ES2142825T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919113164A GB9113164D0 (en) 1991-06-18 1991-06-18 Pharmaceutical agent

Publications (1)

Publication Number Publication Date
ES2142825T3 true ES2142825T3 (es) 2000-05-01

Family

ID=10696898

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92911644T Expired - Lifetime ES2142825T3 (es) 1991-06-18 1992-06-17 Uso de 1(rs)-(1-trifluoroacetil-2-metilpropil)amida de 4-(4-clorofenil-sulfonilcarbamoil)benzoil-l-valil-l-prolina para la preparacion de un medicamento para el tratamiento de enfermedades vasculares.

Country Status (12)

Country Link
EP (1) EP0589937B1 (es)
JP (1) JPH06508826A (es)
AT (1) ATE190493T1 (es)
AU (1) AU667307B2 (es)
CA (1) CA2111846A1 (es)
DE (1) DE69230792T2 (es)
DK (1) DK0589937T3 (es)
ES (1) ES2142825T3 (es)
GB (1) GB9113164D0 (es)
GR (1) GR3032825T3 (es)
NO (1) NO934689D0 (es)
WO (1) WO1992022309A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002161051A (ja) * 1996-12-24 2002-06-04 Fujisawa Pharmaceut Co Ltd 脳虚血性疾患等の治療剤
AT406120B (de) * 1997-08-28 2000-02-25 Immuno Ag Gewebekleber
US6903244B1 (en) * 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
CA2368937A1 (en) * 1999-04-13 2000-10-19 North Shore-Long Island Jewish Research Institute Prevention of brain damage in stroke
IL148924A (en) * 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
US11161859B2 (en) 2017-03-21 2021-11-02 The Scripps Research Institute Cu- and Ni-catalyzed decarboxylative borylation reactions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8600263D0 (en) * 1985-01-22 1986-02-12 Ici America Inc Peptide derivatives
IE911697A1 (en) * 1990-05-24 1991-12-04 Zeneca Ltd Therapeutic agent
DK0458537T3 (da) * 1990-05-24 1999-10-18 Zeneca Ltd Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
GB9014132D0 (en) * 1990-06-25 1990-08-15 Ici Plc Agent for therapy

Also Published As

Publication number Publication date
DE69230792D1 (de) 2000-04-20
GR3032825T3 (en) 2000-06-30
NO934689L (no) 1993-12-17
AU667307B2 (en) 1996-03-21
EP0589937B1 (en) 2000-03-15
GB9113164D0 (en) 1991-08-07
EP0589937A1 (en) 1994-04-06
ATE190493T1 (de) 2000-04-15
JPH06508826A (ja) 1994-10-06
DE69230792T2 (de) 2000-06-29
WO1992022309A1 (en) 1992-12-23
CA2111846A1 (en) 1992-12-23
DK0589937T3 (da) 2000-07-31
AU1900792A (en) 1993-01-12
NO934689D0 (no) 1993-12-17

Similar Documents

Publication Publication Date Title
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
ES2176285T3 (es) Amidas y esteres de peptidos inhibidoras del cancer de seres humanos.
ATE83374T1 (de) Neue galenische form von fenofibrat.
SE9903544D0 (sv) Novel compounds
LU90234I2 (fr) Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine
ES2058680T3 (es) Citrato de l-carnitina y magnesio.
ES2142825T3 (es) Uso de 1(rs)-(1-trifluoroacetil-2-metilpropil)amida de 4-(4-clorofenil-sulfonilcarbamoil)benzoil-l-valil-l-prolina para la preparacion de un medicamento para el tratamiento de enfermedades vasculares.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ITMI910658A0 (it) N-(4,5-diidrossi-e 4,5,8-triidrossi-9,10-diidro-9,10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
SE8802323L (sv) 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
RU99101388A (ru) Способ лечения флеботромбоза в области закрытых переломов костей
ES555466A0 (es) Mejoras introducidas en el objeto de la patente de invencion 516.212 por perfeccionamientos introducidos en atomizadores agricolas
RU96120655A (ru) Композиция для профилактики и лечения гриппа и орви
ITRM940453A0 (it) "uso della proteina p1lsa per la preparazione di un medicamento da utilizzarsi nella terapia di patologie indotte da danni cellulari da agenti fisici, chimici o biologici"
ITMI911048A1 (it) Composizioni farmaceutiche per il trattamento del morbo di parkinson
ES1012331Y (es) Vitrina de esterilizacion por ozono.
TH48054A3 (th) วิธีการรักษาอาธีโรสเคลอโรซิส โดยใช้ตัวยับยั้ง aP2 และสิ่งผสมรวม
IT1230704B (it) Composizione farmaceutica per il trattamento di ictus ischemico.
IT1264562B1 (it) Composizione farmaceutica per l'applicazione topica di 17,b estradiolo nel trattamento della cheratocongiuntivite sicca
MX9203715A (es) Preparciones para el tratamiento del tejido aloinjertado.
TH21240A (th) ควิโนแซลีน กรรมวิธีสำหรับการเตรียมสารเหล่านี้และการใช้สารเหล่านี้
IT9021722A0 (it) Processo per la preparazione di composizioni farmaceutiche per il trattamento delle tossicondipendenze.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 589937

Country of ref document: ES